Generic Name: ranolazine
Brand Name: Corzyna
Manufacturer: KYE Pharmaceuticals Inc.
Therapeutic Area: Stable angina pectoris, adults
Indications: Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Manufacturer Requested Reimbursement Criteria1: Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Submission Type: Initial
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input open | July 17, 2020 |
| Call for patient input closed | September 08, 2020 |
| Clarification: - No patient input submission received | |
| Submission received | August 17, 2020 |
| Submission accepted | August 31, 2020 |
| Review initiated | September 01, 2020 |
| Clarification: - Selected for CADTH/INESSS Joint Clinician Engagement | |
| Draft CADTH review report(s) provided to sponsor for comment | November 17, 2020 |
| Deadline for sponsors comments | November 26, 2020 |
| CADTH responses on draft review report(s) provided to sponsor | January 08, 2021 |
| Expert committee meeting (initial) | January 20, 2021 |
| Draft recommendation issued to sponsor | February 01, 2021 |
| End of embargo period | February 16, 2021 |
| Clarification: - Reconsideration requested | |
| Expert committee meeting | May 19, 2021 |